CD59 CapXM

CD59 CapXM is a gene therapy delivery system developed for targeting central nervous system (CNS) and muscle tissues, with potential application in treating devastating neuromuscular diseases. The platform leverages engineered capsids to enhance gene delivery efficiency and tissue specificity. While the precise mechanism of action for CD59 CapXM as a therapeutic agent is not detailed in the available sources, it is distinct from the endogenous human protein CD59, which functions as a complement inhibitor by preventing formation of the membrane attack complex (MAC). Instead, CD59 CapXM refers specifically to an engineered viral capsid technology designed for improved gene therapy vector performance[2].